BCL2L1 and hepatocellular carcinoma: To test the in vivo efficacy of BCL-xL antagonism to potentiate regorafenib activity against liver cancer, we administered regorafenib and A-1331852 to mice bearing BCLC9 tumors, generated after the subcutaneous injection of this patient-derived HCC cell line.